Ironwood Q3 total revenue $113.7M, GAAP diluted EPS $0.09 vs $0.28 YoY

IRONWOOD PHARMACEUTICALS INC

2023-Q3 EPS reported -$6.45 revenue$325,182,000

Total revenues $113.7M (up 5% YoY); GAAP net income $15.3M, diluted EPS $0.09 vs $0.28.
LINZESS U.S. net sales $279M (+7% YoY); prescription demand +8%.
Positive final data from Phase II STARS Nutrition study of apraglutide in SBS-IF with CIC.
Expects topline data for CNP-104 in primary biliary cholangitis in Q3 2024.
Maintains full year 2023 guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue Total revenues $ 113,739 $ 108,637, net income GAAP net income 13,950 50,317, EPS GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28. Guidance reaffirmed.

Period: the quarter ended September 30, 2023
Revenue: Total revenues $ 113,739 $ 108,637
Net income: GAAP net income 13,950 50,317
EPS: GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the year and meaningful pipeline catalysts ahead in 2024.” Third Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q3 2023 Q3 2022 Total revenues $ 113,739 $ 108,637 Total operating expenses 73,716 40,164 GAAP net income 13,950 50,317 GAAP net income attributable to Ironwood Pharmaceuticals, Inc. 15,321 50,317 GAAP net income

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-115985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.